These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 35118602)
1. SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. Hias J; Hellemans L; Walgraeve K; Tournoy J; Van der Linden L Drugs Aging; 2022 Mar; 39(3):185-190. PubMed ID: 35118602 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M; Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904 [TBL] [Abstract][Full Text] [Related]
3. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Starr JA; Pinner NA Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422 [TBL] [Abstract][Full Text] [Related]
5. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636 [TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F; Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231 [TBL] [Abstract][Full Text] [Related]
11. Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard? Schneider CA; Pfister R Herz; 2022 Oct; 47(5):395-400. PubMed ID: 36018379 [TBL] [Abstract][Full Text] [Related]
12. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Starr JA; Pinner NA; Lisenby KM; Osmonson A Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578 [TBL] [Abstract][Full Text] [Related]
13. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Aimo A; Senni M; Barison A; Panichella G; Passino C; Bayes-Genis A; Emdin M Heart Fail Rev; 2023 Jan; 28(1):179-191. PubMed ID: 35488030 [TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications. Plosker A; Frishman WH Cardiol Rev; 2024 May-Jun 01; 32(3):263-266. PubMed ID: 36728757 [TBL] [Abstract][Full Text] [Related]
15. Management strategies in heart failure with preserved ejection fraction. Wintrich J; Abdin A; Böhm M Herz; 2022 Aug; 47(4):332-339. PubMed ID: 35524007 [TBL] [Abstract][Full Text] [Related]